OnKure Therapeutics (OKUR) director awarded 1,275 stock options at $4.30 strike
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
OnKure Therapeutics, Inc. director Liam Ratcliffe received a grant of stock options covering 1,275 shares of Class A common stock. The options have an exercise price of $4.3000 per share and expire on June 3, 2036. According to the vesting terms, 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the issuer's next annual meeting of stockholders, provided he continues as a service provider through the vesting date. Following this grant, he holds 1,275 derivative securities directly in this option award.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Ratcliffe Liam
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 1,275 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 1,275 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 1,275 shares
Exercise price: $4.3000 per share
Expiration date: June 3, 2036
+3 more
6 metrics
Option grant size
1,275 shares
Stock Option (right to buy) granted to director on June 4, 2026
Exercise price
$4.3000 per share
Conversion or exercise price for the stock option
Expiration date
June 3, 2036
Option term end for the 1,275-share grant
Vesting date
June 4, 2027 or earlier
100% vests on earlier of June 4, 2027 or day before next annual meeting
Post-grant holdings
1,275 derivative securities
Total shares following transaction in this option award
Transaction price
$0.0000
Reporting price per derivative share for the grant
Key Terms
Stock Option (right to buy), Class A Common Stock, exercise price, annual meeting of stockholders, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Class A Common Stock financial
"underlying_security_title: Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
exercise price financial
"conversion_or_exercise_price: 4.3000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
annual meeting of stockholders financial
"earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders"
vesting date financial
"subject to the Reporting Person continuing as a service provider through the applicable vesting date"
FAQ
What did OnKure Therapeutics (OKUR) director Liam Ratcliffe receive in this Form 4?
Director Liam Ratcliffe received a stock option grant for 1,275 shares of Class A common stock. The award is reported as a derivative security and represents a compensation-related acquisition, not an open-market stock purchase or sale.
What is the exercise price of Liam Ratcliffe’s OnKure Therapeutics (OKUR) stock options?
The stock options have an exercise price of $4.3000 per share. This is the price at which he can purchase OnKure Therapeutics Class A common stock if and when the options are vested and exercised.
When do Liam Ratcliffe’s OnKure Therapeutics (OKUR) options vest?
All 1,275 option shares vest 100% on the earlier of June 4, 2027 or the day before OnKure Therapeutics’ next annual meeting. Vesting requires that he continues as a service provider through the applicable vesting date.
When do the reported OnKure Therapeutics (OKUR) stock options expire?
The options reported in this Form 4 expire on June 3, 2036. After this expiration date, any unexercised portion of the 1,275-share option grant can no longer be exercised to purchase Class A common stock.
How many OnKure Therapeutics (OKUR) derivative securities does Liam Ratcliffe hold after this transaction?
Following this grant, he holds 1,275 derivative securities related to this option award. The Form 4 shows total shares following the transaction of 1,275, all held directly as stock options tied to Class A common stock.